<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076594</url>
  </required_header>
  <id_info>
    <org_study_id>LEGA</org_study_id>
    <secondary_id>2011-005537-39</secondary_id>
    <nct_id>NCT02076594</nct_id>
  </id_info>
  <brief_title>Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer</brief_title>
  <official_title>A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regione Lombardia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, parallel group, non-blinded phase III trial. Patients with advanced
      (locoregional or metastatic) gastric cancer not previously treated with chemotherapy for this
      stage will be randomized in a 1:1 ratio to receive low-TOX (arm A) or EOX (arm B).
      Randomization will be stratified by performance status (ECOG 0, 1 and 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the incidence of the adenocarcinoma of the stomach is slowly decreasing, gastric
      cancer represents the second worldwide cause of cancer death after lung cancer. In patients
      with advanced disease, chemotherapy improves survival and quality of life. Combinations of
      two or three drugs including a platin derivative (cisplatin or oxaliplatin), a
      fluoropyrimidine (5FU or capecitabine) and an anthracycline (usually epirubicin) have
      demonstrated superiority compared to single or double agent therapy and are the current
      standard. As of today there are no published studies comparing anthracycline-based to
      taxane-based three-drug regimens. The objective of the present study is to compare EOX as
      evaluated in REAL-2 to the low-TOX regimen consisting of docetaxel, oxaliplatin and
      capecitabine. Low-TOX is expected to be better tolerated than the original DCF regimen. The
      study will be performed in the HER2 negative patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The interim analysis performed on 09 November 2018, showed the failure to achieve the primary
    objective of effectiveness of the experimental treatment.
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Measured as the time from randomization to the date of local or regional progression, distant metastasis, second primary malignancy or death, assessed up to 18 months of follow up</time_frame>
    <description>To determine the progression free survival (PFS) of patients with locally advanced unresectable or metastatic gastric cancer treated with Docetaxel plus Oxaliplatin plus Capecitabine (Arm A) or with Epirubicin plus Oxaliplatin plus Capecitabine (Arm B)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Measured as the time from randomization to the date of death from any cause, assessed up to 18 months of follow up</time_frame>
    <description>To assess overall survival (OS) of patients with locally advanced unresectable or metastatic gastric cancer treated with Docetaxel plus Oxaliplatin plus Capecitabine (Arm A) or with Epirubicin plus Oxaliplatin plus Capecitabine (Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (CR + PR) according to RECIST 1.1 guideline</measure>
    <time_frame>Measured as the time from randomization, assessed up to 18 months of follow up</time_frame>
    <description>To assess objective response rate (CR+PR)of patients with locally advanced unresectable or metastatic gastric cancer treated with Docetaxel plus Oxaliplatin plus Capecitabine (Arm A) or with Epirubicin plus Oxaliplatin plus Capecitabine (Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate: CR + PR + SD lasting &gt; 12 weeks</measure>
    <time_frame>Measured as the time from randomization, assessed up to 18 months of follow up</time_frame>
    <description>To assess disease control rate of patients with locally advanced unresectable or metastatic gastric cancer treated with Docetaxel plus Oxaliplatin plus Capecitabine (Arm A) or with Epirubicin plus Oxaliplatin plus Capecitabine (Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of the treatments evaluated in term of occurrence of: side effects graded according to the NCI-CTCAE scale (version 4.0); serious adverse reactions, expected and unexpected</measure>
    <time_frame>Measured as the time from randomization, assessed up to 18 months of follow up</time_frame>
    <description>To assess tolerability of the treatments of patients with locally advanced unresectable or metastatic gastric cancer treated with Docetaxel plus Oxaliplatin plus Capecitabine (Arm A) or with Epirubicin plus Oxaliplatin plus Capecitabine (Arm B)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Locally Advanced Unresectable Gastric Cancer</condition>
  <condition>Metastatic Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel &amp; Oxaliplatin &amp; Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive cycles every 3 weeks of Docetaxel (35 mg/ m2, intravenous at days 1 and 8 by 1-hour infusion)and Oxaliplatin (80 mg/ m2, intravenous at day 1 by 2-hour infusion) and Capecitabine (750 mg/ m2, oral tablets of 500 and 150 mg, x2 daily for 2 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epirubicin &amp; Oxaliplatin &amp; Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive cycles every 3 weeks of Epirubicin (50 mg/ m2, intravenous on day 1 by 2-hour infusion)and Oxaliplatin (130 mg/ m2, intravenous on day 1 by 2-hour infusion) and Capecitabine (625 mg/ m2,oral tablets of 500 and 150 mg, x2 daily for 3 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Powder for solution for infusion</description>
    <arm_group_label>Docetaxel &amp; Oxaliplatin &amp; Capecitabine</arm_group_label>
    <other_name>Taxotere 20 mg/mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Epirubicin &amp; Oxaliplatin &amp; Capecitabine</arm_group_label>
    <other_name>Farmorubicina 2mg/mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Powder for solution for infusion</description>
    <arm_group_label>Docetaxel &amp; Oxaliplatin &amp; Capecitabine</arm_group_label>
    <arm_group_label>Epirubicin &amp; Oxaliplatin &amp; Capecitabine</arm_group_label>
    <other_name>Eloxatin 5 mg/mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Film coated tablets</description>
    <arm_group_label>Docetaxel &amp; Oxaliplatin &amp; Capecitabine</arm_group_label>
    <arm_group_label>Epirubicin &amp; Oxaliplatin &amp; Capecitabine</arm_group_label>
    <other_name>Xeloda 150 mg</other_name>
    <other_name>Xeloda 500 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent prior to beginning protocol specific procedures

          -  Male or female &gt; 18 years of age

          -  Histologically proven diagnosis of adenocarcinoma of the stomach

          -  HER2 negative tumor or HER2+ tumors not qualifying for herceptin therapy

          -  Locally advanced (non resectable) or metastatic gastric cancer

          -  Presence of measurable disease with at least one measurable lesion by means of CT scan
             or MRI in not previously irradiated area(s) (according to RECIST criteria (version
             1.1)

          -  Life expectancy of &gt;/= 3 months

          -  ECOG performance status of 0-2 at study entry

          -  Neutrophils &gt;/= 2.0 x 1000000000/L, platelets &gt;/= 100 x 1000000000/L, and hemoglobin
             &gt;/= 10 g/dL

          -  Bilirubin level either normal or &lt;/= 1.5 x ULN

          -  AST and ALT &lt;/= 2.5 X UNL (&lt;/= 5 x ULN if liver metastasis are present

          -  Alkaline phosphatase (ALP) &lt;/= 2.5 X ULN; patients with alkaline phosphatase &gt; 2.5x
             ULN and AST and ALT &lt;/= 1.5 x ULN are equally eligible

          -  Serum creatinine &lt; 1.5 x ULN. In presence border-line values, the calculated
             creatinine clearance should be &gt;/= 60 mL/min

          -  Negative pregnancy test (if female in reproductive years)

          -  Effective contraception prior to study entry and for the duration of the study
             participation, for both male and female patients of child producing potential

          -  Able and willing to comply with scheduled visits, therapy plans and laboratory tests
             required in this protocol

        Exclusion Criteria:

          -  Previous chemotherapy, except adjuvant treatment administered at least 1 year before
             study entry

          -  Concurrent chronic systemic immune therapy

          -  Any investigational agent(s) 4 weeks prior to entry

          -  Clinically relevant coronary artery disease or a history of a myocardial infarction or
             a history of hypertension not controlled by therapy within the last 12 months

          -  Known hypersensitivity to study drugs. Known grade 3 or 4 allergic reaction to any of
             the components of the treatment

          -  Known drug abuse/ alcohol abuse

          -  Acute or subacute intestinal occlusion and any other significant chronic
             gastrointestinal disease that might interfere with absorption of oral treatment

          -  History of clinically relevant psychiatric disability precluding informed consent

          -  Presence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule

          -  Pregnant or breastfeeding women

          -  Active uncontrolled infection(s)

          -  Positive for HIV serology and/or viral hepatitis B or C

          -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of
             the cervix. (Patients with a previous malignancy but without evidence of disease for ≥
             5 years will be allowed to enter the trial)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Labianca, MD</last_name>
    <role>Study Director</role>
    <affiliation>A.O. Papa Giovanni XXIII di Bergamo, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrico Cortesi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Umbero I di Roma, UOC Oncologia Medica B</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Domenico Cristiano Corsi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Fatebenefratelli di Roma, Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pietro Sozzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale degli Infermi di Biella, Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi Cavanna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AUSL di Piacenza, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Domenico Bilancia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale San Carlo di Potenza, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosa Rita Silva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASUR Zona 6 di Fabriano, Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Fazio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Istituto Europeo di Oncologia di Milano, Tumori digestivi superiori e Neuroendocrini</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monica Giordano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A. O. Sant'Anna di Como, Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Bertolini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Civile di Sondrio, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Ucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale Maggiore di Lodi, Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donato Natale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. di Pescara - Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daris Ferrari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. San Paolo di Milano, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Graziella Pinotti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale di Circolo e Fondazione Macchi di Varese, Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ermanno Rondini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale di S. Maria Nuova di Reggio Emilia, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Cirillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Sacro Cuore Don Calabria di Negrar, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosario Vincenzo Iaffaioli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Istituto Nazionale Tumori Fondazione Pascale di Napoli, Oncologia Medica Addominale</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Ciarlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Misericordia e Dolce di Prato, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Piazza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale L. Sacco di Milano, Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Libero Ciuffreda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Città della Salute e della Scienza di Torino, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefania Dell'Oro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale di Circolo A. Manzoni di Lecco, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrizio Artioli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale di Carpi, Medicina Oncologica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudio Verusio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Generale Provinciale di Saronno, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincenzo Catalano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedali Riuniti Marche Nord - Presidio S. Salvatore Muraglia, Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudio Graiff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASDAA Bolzano, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Domenico Amoroso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale Versilia di Camaiore, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Di Bartolomeo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medicina Oncologica 1</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Silvestris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Tumori di Bari, Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria C. Zavettieri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OSPED. DI CIRCOLO SERBELLONI-GORGONZOLA - GORGONZOLA (MI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enzo Veltri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OSPEDALE SANTA MARIA GORETTI LATINA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Ferraù, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>P.O. &quot;SAN VINCENZO&quot; TAORMINA - TAORMINA (ME)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giampaolo Tortora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OSPEDALE POLICLINICO G.B. ROSSI (BORGO ROMA) DI VERONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandro Barni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. TREVIGLIO-CARAVAGGIO - TREVIGLIO (BG)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Scartozzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O.U. di Cagliari - Presidio di Monserrato</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Tumori</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Treviglio-Caravaggio</name>
      <address>
        <city>Treviglio</city>
        <state>BG</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Cagliari</name>
      <address>
        <city>Monserrato</city>
        <state>CA</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Anna</name>
      <address>
        <city>Como</city>
        <state>CO</state>
        <zip>22020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo A. Manzoni</name>
      <address>
        <city>Lecco</city>
        <state>LC</state>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Goretti Latina</name>
      <address>
        <city>Latina</city>
        <state>LT</state>
        <zip>04100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Versilia</name>
      <address>
        <city>Camaiore</city>
        <state>LU</state>
        <zip>55041</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. &quot;San Vincenzo&quot; Taormina</name>
      <address>
        <city>Taormina</city>
        <state>ME</state>
        <zip>98039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osped. Di Circolo Serbelloni-Gorgonzola</name>
      <address>
        <city>Gorgonzola</city>
        <state>MI</state>
        <zip>20064</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Europeo di Oncologia (IEO)</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Paolo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale L. Sacco</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Carpi</name>
      <address>
        <city>Carpi</city>
        <state>MO</state>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSL di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Marche Nord - Presidio S. Salvatore Muraglia</name>
      <address>
        <city>Pesaro</city>
        <state>PE</state>
        <zip>61122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. O. di Pescara - Ospedale Civile Spirito Santo</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Misericordia e Dolce</name>
      <address>
        <city>Prato</city>
        <state>PO</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <state>PZ</state>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi di Varese</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore Don Calabria di Negrar</name>
      <address>
        <city>Negrar</city>
        <state>VR</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale Tumori Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

